Noninvasive disconnection of targeted neuronal circuitry sparing axons of passage and nonneuronal cells.
Authors: Wang Y, Anzivino MJ, Zhang Y, Bertram EH, Woznak J, Klibanov AL, Dumont E, Wintermark M, Lee KS
Surgery can be highly effective for the treatment of medically intractable, neurological disorders, such as drug-resistant focal epilepsy. However, despite its benefits, surgery remains substantially underutilized due to both surgical concerns and nonsurgical impediments. In this work, the authors characterized a noninvasive, nonablative strategy to focally destroy neurons in the brain parenchyma with the goal of limiting collateral damage to nontarget structures, such as axons of passage. Low-intensity MR-guided focused ultrasound (MRgFUS), together with intravenous microbubbles, was used to open the blood-brain barrier (BBB) in a transient and focal manner in rats. The period of BBB opening was exploited to focally deliver to the brain parenchyma a systemically administered neurotoxin (quinolinic acid) that is well tolerated peripherally and otherwise impermeable to the BBB. Focal neuronal loss was observed in targeted areas of BBB opening, including brain regions that are prime objectives for epilepsy surgery. Notably, other structures in the area of neuronal loss, including axons of passage, glial cells, vasculature, and the ventricular wall, were spared with this procedure. These findings identify a noninvasive, nonablative approach capable of disconnecting neural circuitry while limiting the neuropathological consequences that attend other surgical procedures. Moreover, this strategy allows conformal targeting, which could enhance the precision and expand the treatment envelope for treating irregularly shaped surgical objectives located in difficult-to-reach sites. Finally, if this strategy translates to the clinic, the noninvasive nature and specificity of the procedure could positively influence both physician referrals for and patient confidence in surgery for medically intractable neurological disorders.
Introduction
Purpose
Drug delivery with BBB opening
Study Objective
To characterize a noninvasive, nonablative MR-guided focused ultrasound approach using transient blood–brain barrier opening and systemic neurotoxin delivery to focally destroy neurons while limiting collateral damage to nontarget structures.
Animal model / Human subject
rat, Sprague-Dawley, 5–6 weeks, male
Disease model
epilepsy
MRI or image guidance method
MR-guided focused ultrasound (MRgFUS)
Targeted brain region(s)
Hippocampus
Cargo name and characteristics
drug
Route of administration
intravenous
Outcomes and Safety
Summary of Outcomes
FUS-mediated BBB opening delivered systemic quinolinic acid to produce focal neuronal loss while sparing axons and glia
Duration of biological effect
not reported
Safety-related matter
Focal neuronal loss achieved with limited collateral damage to vasculature and glial cells
Brain Region
Ultrasound Parameters
Ultrasound instrument
RK-100 MR-compatible FUS system
FUS Frequency
1.1 MHz
FUS Intensity
not reported
FUS Pressure
0.45 MPa
FUS Mode
not reported
Pulse duration
10 ms
Duration of a single FUS session
120 s
Treatment frequency
Single session
We are open to feedback. If you see a mistake or have a suggestion, please contact us.
← Back to Search